Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Open for business: How universities can boost our long-term recovery

2 August 2013

By Stephen Caddick
In today’s global marketplace, Britain must grow as a hub of innovation. London – already one of the largest city economies in the world – is a nexus of global trade. To maintain this lead, we need to muster every ounce of competitive advantage.

Read the full article